Compounds and radioligands for targeting neurotensin receptor and uses thereof
US12145926B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Mar 13, 2024 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Mar 13, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D231/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application relates to a compound of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, or a radionuclide complex comprising a compound of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, and one or more radionuclides, and to compositions thereof. The present application also includes methods of using the compounds, complexes and compositions for targeting neurotensin receptors, and further to their use in the imaging, diagnosis and treatment of diseases, disorders or conditions such as cancer. The present application relates to a compound of Formula (II) or a pharmaceutically acceptable salt and/or solvate thereof, and to compositions and uses thereof, for example, in the treatment of diseases, disorders or conditions such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.